Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells

FLT3 internal tandem duplication (ITD) mutations are associated with poor prognosis in patients with acute myeloid leukemia (AML). In this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of...

Descripción completa

Detalles Bibliográficos
Autores principales: Aikawa, Tomoya, Togashi, Noriko, Iwanaga, Koichi, Okada, Hiroyuki, Nishiya, Yumi, Inoue, Shinichi, Levis, Mark J., Isoyama, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082118/
https://www.ncbi.nlm.nih.gov/pubmed/32215183
http://dx.doi.org/10.18632/oncotarget.27489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082118/
https://www.ncbi.nlm.nih.gov/pubmed/32215183
http://dx.doi.org/10.18632/oncotarget.27489

Ejemplares similares